Upadacitinib (Rinvoq) for Ulcerative Colitis: A Patient Guide

Upadacitinib, sold under the brand name Rinvoq, is an oral JAK inhibitor approved for moderate to severe ulcerative colitis. It is one of the newest and most effective UC medications available, offering the convenience of a once-daily pill with strong clinical trial results — including in patients who have already tried and failed other treatments. This guide explains how upadacitinib works, what to expect during treatment, the risks you need to understand before starting, and what to discuss with your gastroenterologist.

How Does Upadacitinib Work?

Upadacitinib belongs to a class of medications called JAK inhibitors — drugs that block enzymes called Janus kinases (JAKs) that play a central role in the inflammatory signaling pathways driving UC. Specifically, upadacitinib is JAK1-selective, meaning it primarily targets JAK1, which is the kinase most involved in the intestinal inflammatory response in UC. This selectivity is significant — earlier JAK inhibitors like tofacitinib were less selective, and the greater JAK1 specificity of upadacitinib is thought to contribute to its efficacy and side effect profile.

The medication works inside the cell, blocking the intracellular signaling cascades that tell the immune system to produce inflammation. This is fundamentally different from biologics, which work outside cells by targeting specific proteins in the bloodstream or on cell surfaces. JAK inhibitors can therefore potentially act on pathways that biologics cannot reach, which is one reason they show efficacy in patients who have not responded to biologic therapy.

From a practical standpoint, upadacitinib’s most important feature for many patients is its delivery method: it is taken as a once-daily oral tablet. No injections, no infusions, no infusion center visits. For patients who are fatigued by the logistics of biologic administration, this represents a meaningful quality-of-life advantage.

• JAK1-selective inhibitor — blocks intracellular inflammatory signaling pathways
• Oral once-daily tablet — no injections or infusions required
• Works at a different point in the inflammatory cascade than biologics
• Approved for adults with moderate to severe UC after failure of other therapies

Who Is Upadacitinib Prescribed For?

Upadacitinib is indicated for adults with moderate to severe active UC. In clinical practice, it is most often considered in patients whose disease has not been adequately controlled despite trying other options.

The most common scenario is a patient who has failed one or more biologic medications — whether TNF inhibitors like infliximab or adalimumab, or gut-selective biologics like vedolizumab. The U-ACHIEVE and U-ACCOMPLISH clinical trials, which led to upadacitinib’s FDA approval in UC, specifically included a significant proportion of biologic-experienced patients, and the results in this group were impressive — a population that is often the hardest to treat.

Upadacitinib is also used in patients who have not tried biologics but whose disease is moderate to severe and has not responded to conventional therapy (mesalamine, corticosteroids, or immunomodulators). Some gastroenterologists are increasingly willing to consider it earlier in the treatment sequence, particularly for patients with severe disease or features suggesting a poor prognosis.

Patients who prefer an oral medication over biologic injections or infusions may be particularly suited to upadacitinib, especially when the clinical profile is otherwise appropriate.

Upadacitinib is not recommended during pregnancy. Adequate contraception is required while taking it, and a discussion about reproductive plans should happen before starting the medication.

Dosing — Induction and Maintenance

Upadacitinib uses a two-phase dosing strategy: a higher induction dose for the initial weeks, followed by a lower maintenance dose once the disease is under control.

Induction: 45 mg once daily for 8 weeks. This higher dose is designed to achieve rapid control of active inflammation.

Maintenance: After induction, the dose is reduced. The standard maintenance options are 15 mg or 30 mg once daily, with the choice determined by how well the disease responded during induction and what level of ongoing suppression is needed. Patients with more severe or treatment-refractory disease may remain on 30 mg maintenance; others can be stepped down to 15 mg.

The tablet is an extended-release formulation and should be taken whole — it should not be crushed, split, or chewed. It can be taken with or without food. Consistent daily dosing at approximately the same time each day supports stable drug levels.

• Induction: 45 mg once daily for 8 weeks
• Maintenance: 15 mg or 30 mg once daily based on response
• Extended-release tablet — take whole, do not crush or split
• Can be taken with or without food

How Quickly Does Upadacitinib Work?

One of upadacitinib’s most clinically significant advantages is its speed of action. Unlike biologics — which typically require weeks to months to reach full effect — upadacitinib can produce meaningful symptom improvement within the first two to four weeks of the induction phase.

In the clinical trials, many patients experienced significant reductions in stool frequency and rectal bleeding within the first two weeks. By week 8 of induction, remission rates in the trials were 26 to 34 percent in biologic-naive patients, with clinical response rates considerably higher. In biologic-experienced patients — a harder-to-treat population — the results were still clinically meaningful.

This rapid onset makes upadacitinib particularly attractive for patients who are in significant distress from active symptoms and need relief quickly. It also means that the waiting period while the medication takes effect is shorter than for most biologic options — which matters enormously to patients who are experiencing daily bloody diarrhea, urgency, and cramping.

The full depth of response — including endoscopic healing of the colon lining — continues to develop over months, and achieving endoscopic remission is increasingly the target that gastroenterologists aim for beyond symptom control alone.

Upadacitinib Side Effects and Risks

Upadacitinib is an effective medication, but it carries a meaningful risk profile that must be understood before starting. The FDA requires a black box warning — its most serious level — for the JAK inhibitor class as a whole, and upadacitinib carries this warning. Understanding what the risks are and their actual magnitude helps patients make informed decisions rather than either dismissing the warning or being unnecessarily frightened by it.

Common side effects reported in clinical trials include upper respiratory infections (colds), acne, headache, nausea, and fever. Acne is particularly notable — it occurs more frequently than with other UC medications and can be bothersome, though it is usually manageable with topical treatment.

The black box warning covers four serious risk categories:

Serious infections, including tuberculosis, bacterial infections, invasive fungal infections, and other opportunistic infections. Because upadacitinib suppresses immune signaling pathways, it reduces the body’s ability to fight certain infections. TB screening is required before starting, and patients should report any signs of infection — fever, chills, unusual fatigue, cough — promptly during treatment.

Malignancy, including lymphoma and other cancers. JAK inhibitors as a class have been associated with an increased risk of certain malignancies, particularly lymphoma. The absolute risk in clinical trials was low, but the signal was significant enough to warrant the warning. Patients with a history of certain cancers should discuss this risk carefully with their oncologist and gastroenterologist.

Major adverse cardiovascular events (MACE), including heart attack and stroke. This risk is most relevant in patients aged 50 and older with existing cardiovascular risk factors (smoking, high blood pressure, high cholesterol, diabetes, family history). The signal emerged most clearly from studies in rheumatoid arthritis patients and has been extrapolated to the class. Patients without cardiovascular risk factors face a much lower absolute risk.

Thrombosis, including deep vein thrombosis and pulmonary embolism. Blood clots are a monitored risk. Report any leg swelling, pain, redness, or sudden shortness of breath immediately.

Important context: These risks are real and should not be minimized. But they are also relatively uncommon, and they are exactly why your gastroenterologist will screen carefully before starting and monitor regularly during treatment. The black box reflects appropriate caution for the class — it does not mean upadacitinib is the wrong choice for patients who need it and do not have elevated risk factors. Many thousands of patients have been treated with upadacitinib in clinical trials and real-world practice with good outcomes.

Upadacitinib vs Biologics

The decision between upadacitinib and a biologic medication is one of the most common treatment discussions for patients with moderate to severe UC. Both categories are effective, and neither is universally superior — the right choice depends on the individual patient.

Upadacitinib advantages over most biologics: Oral pill convenience, faster onset of action, demonstrated efficacy in biologic-experienced patients, and a single daily dose rather than scheduled infusions or injections.

Biologic advantages over upadacitinib: Longer safety track records for some agents, no black box warning (for vedolizumab in particular), different risk profiles that may be preferable for specific patient populations (older patients, those with cardiovascular risk factors), and strong safety data in pregnancy and breastfeeding.

Upadacitinib tends to be particularly useful for patients who have already failed biologic therapy — where its different mechanism may achieve results that biologics could not. For a deeper comparison of JAK inhibitors as a class, see our guide on JAK inhibitors for ulcerative colitis. For a side-by-side overview of all major UC treatment options, see our UC treatment comparison guide.

The decision between upadacitinib and a specific biologic should always involve your gastroenterologist, who can weigh your treatment history, risk factors, preferences, and disease characteristics.

Important Safety Monitoring

Starting upadacitinib involves a structured pre-treatment screening process and ongoing monitoring while you are on the medication. This is not bureaucratic — it is how the risks are managed in practice.

Before starting:

• TB skin test or blood test (IGRA) — to rule out latent tuberculosis before immune suppression begins
• Complete blood count — baseline white cell count, hemoglobin, platelet count
• Liver function tests and lipid panel — baseline values before treatment
• Review of vaccination history — live vaccines should not be given while on upadacitinib; catch up on vaccinations before starting

During treatment:

• Blood counts, lipids, and liver function every 3 months initially, then at regular intervals
• Skin monitoring — annual skin checks are recommended given the increased non-melanoma skin cancer risk
• Ongoing vigilance for signs of infection

Report immediately: Any signs of infection (fever, unusual fatigue, productive cough), signs of blood clots (leg pain, swelling, sudden chest pain or shortness of breath), unusual skin changes, or any new lumps or masses.

Questions to Ask Your Doctor About Upadacitinib

• Am I a good candidate given my age and cardiovascular history? The risk-benefit calculation is different for a 35-year-old with no cardiovascular history than for a 60-year-old who smokes.
• What screening do I need before starting? Understand the pre-treatment workup and any vaccines you should get in advance.
• What dose will I start on and how will we decide the maintenance dose? Know the induction plan and the criteria for stepping down.
• What monitoring will I need while on Rinvoq? Get a clear picture of how often you will need blood tests and what they will check.
• What are the signs I should call you about immediately? Know the red flags before you need them.
• Is there a patient assistance program available? Upadacitinib is expensive. AbbVie (the manufacturer) offers patient support programs — ask your GI doctor’s office about a patient services contact or nurse navigator.

For a broader list of questions to bring to your gastroenterologist — including questions about treatment escalation and long-term monitoring — see our GI doctor questions checklist.

Medical Disclaimer

This article is for educational purposes only and does not constitute medical advice. The risks and benefits of upadacitinib must be evaluated individually based on your medical history, age, cardiovascular risk factors, prior treatment history, and other considerations. Always consult your gastroenterologist before making any decisions about your UC treatment.